Encube Ethicals, Inc. announced on Tuesday, March 5th, that its generic estradiol topical gel has received FDA approval under application ANDA218507, positioning the company to compete directly with branded hormone replacement therapy products. This regulatory green light is likely to impact market dynamics, potentially driving price compression within the estrogen gel segment and expanding Encube’s revenue base in the hormone therapy landscape.